Salani R - Search Results

1

Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).

Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ. Tewari KS, et al. Among authors: salani r. Mol Cancer Ther. 2020 Nov;19(11):2363-2370. doi: 10.1158/1535-7163.MCT-20-0276. Epub 2020 Aug 26. Mol Cancer Ther. 2020. PMID: 32847980 Free PMC article. Clinical Trial.

2

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.

Hurt JD, Richardson DL, Seamon LG, Fowler JF, Copeland LJ, Cohn DE, Eisenhauer E, Salani R, O'Malley DM. Hurt JD, et al. Among authors: salani r. Gynecol Oncol. 2009 Dec;115(3):396-400. doi: 10.1016/j.ygyno.2009.08.032. Epub 2009 Oct 4. Gynecol Oncol. 2009. PMID: 19804901

3

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.

O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, Fowler JM, Copeland LJ, Cohn DE, Backes FJ. O'Malley DM, et al. Among authors: salani r. Gynecol Oncol. 2011 May 1;121(2):269-72. doi: 10.1016/j.ygyno.2011.01.009. Epub 2011 Feb 18. Gynecol Oncol. 2011. PMID: 21315428

4

Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer.

Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O'Malley DM, Fowler JM, Copeland LJ, Salani R. Nagel CI, et al. Among authors: salani r. Gynecol Oncol. 2012 Feb;124(2):221-4. doi: 10.1016/j.ygyno.2011.10.003. Epub 2011 Nov 4. Gynecol Oncol. 2012. PMID: 22055764 Free PMC article.

5

A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.

Rose PG, Sill MW, McMeekin DS, Ahmed A, Salani R, Yamada SD, Wolfson AH, Fusco N, Fracasso PM. Rose PG, et al. Among authors: salani r. Gynecol Oncol. 2012 Apr;125(1):158-62. doi: 10.1016/j.ygyno.2011.12.431. Epub 2011 Dec 22. Gynecol Oncol. 2012. PMID: 22198338 Free PMC article. Clinical Trial.

6

Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

McCann GA, Smith B, Backes FJ, Rath K, Chacko S, Salani R, Eisenhauer E, Fowler JM, Cohn DE, O'Malley DM. McCann GA, et al. Among authors: salani r. Gynecol Oncol. 2012 Nov;127(2):362-6. doi: 10.1016/j.ygyno.2012.08.001. Epub 2012 Aug 10. Gynecol Oncol. 2012. PMID: 22885866 Free PMC article.

7

The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.

McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, O'Malley DM, Copeland LJ, Cohn DE, Salani R. McCann GA, et al. Among authors: salani r. Gynecol Oncol. 2013 Jan;128(1):44-48. doi: 10.1016/j.ygyno.2012.10.028. Epub 2012 Nov 5. Gynecol Oncol. 2013. PMID: 23138134 Free PMC article.

8

Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.

McCann GA, Boutsicaris CE, Preston MM, Backes FJ, Eisenhauer EL, Fowler JM, Cohn DE, Copeland LJ, Salani R, O'Malley DM. McCann GA, et al. Among authors: salani r. Gynecol Oncol. 2013 Apr;129(1):135-9. doi: 10.1016/j.ygyno.2013.01.014. Epub 2013 Jan 26. Gynecol Oncol. 2013. PMID: 23357610

9

Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.

Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM, Cohn DE, Copeland LJ, Eisenhauer EL, Salani R. Rath KS, et al. Among authors: salani r. Gynecol Oncol. 2013 Apr;129(1):103-6. doi: 10.1016/j.ygyno.2013.01.021. Epub 2013 Jan 29. Gynecol Oncol. 2013. PMID: 23369942 Free PMC article.

10

Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?

Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DM. Backes FJ, et al. Among authors: salani r. Int J Gynecol Cancer. 2013 Jun;23(5):833-8. doi: 10.1097/IGC.0b013e318290ea69. Int J Gynecol Cancer. 2013. PMID: 23640292

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters